Suppression of tumor suppressors in prostate cancer: the emergence of a novel oncogenic pathway.
Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, Yu and colleagues show that repression of Adrenergic Receptor Beta-2 gene expression by Enhancer of Zeste 2 results in acquisition of transforming activities. It is interesting that these activities point to a role for GTPases as important regulators of transformation in prostate cancer cells. They further implicate epithelial-mesenchymal transition as a biologic end point in this process. Overall, on the basis of their findings, the authors nominate a novel oncogenic pathway for prostate cancer that deserves critical thought and attention.
Thompson
Timothy C
TC
Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. timthomp@mdanderson.org
D000818:Animals; D045744:Cell Line, Tumor; D000242:Cyclic AMP / Q000378:metabolism; D020558:GTP Phosphohydrolases / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008954:Models, Biological; D009857:Oncogenes / Q000235:genetics*; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000473:pathology*; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism*; D000089804:Shelterin Complex; D034501:Telomere-Binding Proteins / Q000378:metabolism
D018343:Receptors, Adrenergic, beta-2; D000089804:Shelterin Complex; C440809:TERF2IP protein, human; D034501:Telomere-Binding Proteins; D000242:Cyclic AMP; D020558:GTP Phosphohydrolases